8/16/2011 | CVHYPF | Inhibitex files $130 million shelf covering preferreds, debt, stock
|
3/30/2010 | CVHYPF | Inhibitex files $100 million shelf covering preferreds, debt, stock
|
10/28/2009 | PP | New Issue: Inhibitex sells $23 million of common shares through private placement
|
10/23/2009 | PP | New Issue: Inhibitex to raise $23 million from private placement of equity units
|
10/23/2009 | PP | Market Commentary: Inhibitex aims for $23 million; BioTie secures SEDA; Discovery settles A$13 million placement
|
12/22/2006 | SS | Inhibitex falls more than 5%; SciClone seen as takeover target; El Paso gains on asset sale
|
11/7/2006 | BT | Inhibitex ends quarter with $64.5 million of cash and equivalents
|
8/3/2006 | BT | Inhibitex seeking late-stage pipeline opportunities, reports $7.7 million second quarter net loss
|
6/29/2006 | BT | Inhibitex to seek corporate partners; plans to continue development of Mscramm platform to prevent, treat infections
|
6/26/2006 | BT | Market Commentary: Vasogen plunges 74%; Anadys falls 45%; Nastech, Amylin gain on pact; Neurocrine finds buyers
|
4/28/2006 | BT | Inhibitex to halt manufacture of Veronate trial material, end relationship with Nabi
|
4/21/2006 | BT | Inhibitex lays off 42% of workforce, expects to save $3.5 million annually
|
4/3/2006 | BT | Inhibitex says infection treatment Veronate fails to meet endpoints in phase 3 trial
|
4/3/2006 | BT | Market Commentary: Epix up 21% on Predix buy; Incyte falls 41%; Medarex off; Inhibitex plunges 66%; StemCells dives
|
2/14/2006 | BT | Inhibitex sets rapid course for use of Veronate in low birth weight infants
|
12/16/2005 | BT | Inhibitex says Aurexis, antibiotic combination results in faster recovery; more tests planned
|
12/5/2005 | BT | Inhibitex's safety board recommends completion of Veronate phase 3 trial
|
11/29/2005 | BT | Inhibitex: FDA may OK Veronate for sub-group of low birth weight babies, European regulators grant orphan status
|
11/16/2005 | BT | Inhibitex says last patient enrolled in phase 3 trial for Veronate to prevent infections in premature infants
|
10/19/2005 | BT | Inhibitex files $125 million stock, warrants shelf
|
8/19/2005 | PP | Market Commentary: Vyteris leads sluggish day for PIPEs with $10 million deal; volume weak at week's end
|
8/18/2005 | BT | Market Commentary: Myogen shoots higher on trial data; Par Pharma buyers hoping for deal; Del Labs bonds fall; Cephalon up
|
8/18/2005 | PP | Market Commentary: Inhibitex leads PIPE news with $41.25 million issue; issuance slow in U.S. market
|
8/18/2005 | BTPP | New Issue: Inhibitex raises $41.25 million in private placement of stock
|
11/10/2004 | PP | New Issue: Inhibitex closes $50 million private placement of shares, warrants
|
11/10/2004 | PP | Market Commentary: Private placement volume strengthens on better oil prices; Inhibitex closes $50 million deal
|
11/5/2004 | PP | New Issue: Inhibitex to raise $50 million in private placement of shares, warrants
|
11/5/2004 | PP | Market Commentary: Private placement volume strong as week ends; Inhibitex raises $50 million
|